Dinaciclib - Merck & Co
Alternative Names: MK-7965; PS-095760; SCH 727965; SCHOOL 727965Latest Information Update: 05 Nov 2023
At a glance
- Originator Pharmacopeia
- Developer AbbVie; Baylor College of Medicine; Merck & Co; University of California at San Francisco
- Class Antineoplastics; Small molecules
- Mechanism of Action Apoptosis stimulants; CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic lymphocytic leukaemia
- Phase I Acute myeloid leukaemia; Breast cancer
- Preclinical Hepatoblastoma
- No development reported Non-small cell lung cancer
- Discontinued Leukaemia; Mantle-cell lymphoma
Most Recent Events
- 10 Dec 2022 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 01 Dec 2022 AbbVie in collaboration with Merck Sharp & Dohme terminates phase Ib trial in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in Spain, Australia and US (IV), due to strategic considerations (NCT03484520)
- 29 Sep 2022 Dinaciclib is still in phase I trials for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, In adults, In the elderly) in USA (IV) (NCT01676753)